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Original Article
INTRODUCTION
Carcinomas of the external auditory canal (EAC) are very rare, 
accounting for only 0.2% of all tumors of the head and neck [1]. 
Given such paucity, few epidemiological data are available and 
no consensus on management has emerged. Early diagnosis is 
often difficult; biopsy is recommended in suspicious cases with 
EAC skin lesions [2]. Furthermore, treatment remains challeng-
ing due to the lack of reliable clinical and pathological prognos-
tic factors, and the markedly diverse surgical and oncological 
treatment modalities available. Although no staging system for 
EAC carcinomas is currently recognized by either the Union for 
International Cancer Control or the American Joint Committee 
on Cancer, a comprehensive staging system developed by Arria-
ga et al. [3] and later modified by Moody et al. [1], namely the 
Pittsburgh Tumor Staging System, is most widely used [4,5]. In 
addition, advancements in radiological imaging including com-
puted tomography (CT), magnetic resonance imaging (MRI), 
and positron emission tomography have provided clinicians with 
in-depth information that aids in preoperative staging and plan-
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Objectives. Carcinomas of the external auditory canal (EAC) are rare, and management remains challenging. Previous 
studies seeking prognostic factors for EAC cancers included cancers other than carcinomas. In this study, we analyzed 
the treatment outcomes of, prognostic factors for, and survival rates associated with specifically squamous cell carci-
noma (SCC) of the EAC. 
Methods. A retrospective review of 26 consecutive patients diagnosed with SCCs of the EAC in a 10-year period was per-
formed in terms of clinical presentation, stage, choice of surgical procedure, and adjunct therapy. Overall survival (OS) 
and recurrence-free survival (RFS) were calculated and univariate analysis of prognostic factors was performed. 
Results. The median age of the 26 patients with SCCs of the EAC was 63 years (range, 40 to 72 years), and 16 males and 
10 females were included. According to the modified University of Pittsburgh staging system, the T stages were T1 in 
11, T2 in six, T3 in four, and T4 in five cases. The surgical procedures employed were wide excision in three cases, lat-
eral temporal bone resection (LTBR) in 17, and extended LTBR in four, and subtotal temporal bone resection in two. 
Two patients underwent neoadjuvant chemotherapy, and two underwent adjuvant chemotherapy. One patient re-
ceived preoperative radiation therapy, and eleven received postoperative radiation therapy. Of the possibly prognostic 
factors examined, advanced preoperative T stage and advanced overall stage were significant predictors of RFS, but 
not of OS. 
Conclusion. The advanced T stage and overall stage were associated with decreased survival after surgical treatment in pa-
tients with SCC of the EAC, highlighting the importance of clinical vigilance and early detection. 
Keywords. External Auditory Canal; Ear Neoplasms; Squamous Cell Carcinoma; Temporal Bone 
260    Clinical and Experimental Otorhinolaryngology    Vol. 11, No. 4: 259-266, December 2018
ning [4]. Treatment options include wide surgical resection, ra-
diotherapy, chemotherapy, or combinations of these modalities. 
In operable cases, surgical approaches seek to achieve en bloc 
resection of the temporal bone using sleeve resection, lateral 
temporal bone resection (LTBR), or subtotal temporal bone re-
section (STBR), any of which can be combined with parotidec-
tomy and/or neck dissection followed by (postoperative) radio-
therapy [5-7]. However, the complexity of the anatomy and the 
relationship between the tumor with surrounding tissues within 
a limited space, render it difficult to attain safe resection margins 
[7]. The aim of this study was to report the treatment outcomes 
of patients with squamous cell carcinoma (SCC) of the EAC and 
to identify prognostic factors for survival in patients with this 
disease.
MATERIALS AND METHODS
 
This study included consecutive patients with histologically 
proven SCC of the EAC who underwent surgery between 2006 
and 2016 at Severance Hospital and Gangnam Severance Hos-
pital of Yonsei University Health System, Seoul, Korea. Retro-
spective review of the medical records was performed. The Insti-
tutional Review Board of Gangnam Severance Hospital re-
viewed and approved this study (IRB No. 3-2017-0219). As this 
was a retrospective study, no informed consent was required. 
Exclusion criteria were patients younger than 18 years of age or 
patients who had undergone treatment and recurrence occurred 
before initial presentation. Diagnostic work-up including physi-
cal examination, high-resolution CT and MRI, and preoperative 
biopsy was performed for all patients. The modified University 
of Pittsburgh staging system was used to assess the extents of 
primary and metastatic tumors for preoperative and pathologi-
cal staging. Clinical presentation including, age, sex, date of diag-
nosis, sites of origin (bony and cartilaginous portions of EAC), 
and presence of ipsilateral facial nerve palsy or hearing loss were 
reviewed. The surgical treatment modalities included wide exci-
sion, LTBR, extended LTBR, or STBR, depending on the extent 
of the primary tumor. Total parotidectomy was indicated when 
the anterior growth of the tumor extended beyond the anterior 
wall of the EAC, whereas superficial parotidectomy was prophy-
lactically performed on the intraparotid nodes in cases of T1 and 
T2 disease. Parotid involvement was suspected when imaging 
revealed erosion of the anterior wall of the auditory canal or an 
enhancing mass in the parotid area. During both LTBR and 
STBR, selective prophylactic neck dissection was performed on 
clinically negative necks, and modified radical neck dissection 
was performed on necks with clinically positive lymph nodes. 
Histologic grades and resection margin status were reviewed. 
Adjuvant postoperative chemoradiotherapy was prescribed for 
cases with positive or close resection margins, or clinically suspi-
cious nodal involvement. 
One patient was lost to follow up within 1 year after surgery, 
and remaining 25 patients were included for survival analysis. 
Overall survival (OS) was defined as the length of time from the 
start of treatment to the date of death from any cause or last 
follow-up, and recurrence-free survival (RFS), as the length of 
time after surgery for EC cancer until recurrence of cancer or 
last follow-up. 
Statistical analyses were performed with the aid of SAS ver. 
9.3 (SAS Institute Inc., Cary, NC, USA). Continuous variables 
were compared by the Mann-Whitney U-test, and categorical 
variables between two groups were compared using two-sided 
Fisher exact or the chi-square test. Survival rates were estimated 
using the Kaplan-Meier method and univariate survival analysis 
was completed using the log-rank test. A P-value <0.05 was 
considered statistically significant.
RESULTS
Between January 2006 and December 2016, 40 patients were 
newly diagnosed with EAC cancers and underwent surgical 
treatment. Twenty-six patients were diagnosed with SCC, eight 
with adenocystic carcinoma, five with adenocarcinoma, and one 
patient with basal cell carcinoma. We included 26 patients with 
confirmed SCC of the EAC for data analysis. One patient was 
lost to follow up within 1 year postoperatively, and was exclud-
ed from survival analysis. The patients included 16 males and 10 
females, with a median age of 63 years (range, 40 to 72 years). 
The mean follow-up period was 2.9±1.9 years. The site of in-
volvement at presentation was the bony canal in nine patients 
(33.3%), the cartilaginous canal in four (14.8%), both bony and 
cartilaginous canals in eight (29.6%), and unspecified in five pa-
tients (18.5%) (Table 1). The most common presenting symptom 
was otorrhea (nine patients, 33.3%). Facial nerve palsy was 
present in three cases (11.6%). Mass lesions in the EAC were 
visible otoscopically visible in most patients (24 cases, 92.3%), 
except for two cases where only ulcerative lesions were evident 
in previously mastoidectomized ears. 
Employing the University of Pittsburgh staging system, the T 
   Early tumor stage squamous cell carcinomas of the external 
auditory canal had good prognosis and lower rate of recur-
rence compared to advanced cases. 
   Among the prognostic factors analyzed, advanced tumor stag-
es and neck node recurrence were associated with poor treat-
ment outcomes. 
   Our results highlight the importance of early diagnosis and 
surgical treatment for squamous cell carcinomas of the exter-
nal auditory canal.
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stages were T1 in 11 patients (42.3%), T2 in six (23.1%), T3 in 
four (15.4%), and T4 in five (19.2%). Preoperative regional 
lymph node involvement was evident in three patients (12%); 
two patients (7.7%) had stage N1 cancer and one (3.8%) had 
stage N2 cancer. All of the patients underwent surgery; the sur-
gical procedures included wide excision in three patients (11.5%), 
LTBR in 17 (65.4%), extended LTBR in four (14.8%), and STBR 
in two (7.1%). On pathological examination, tumor-free margins 
were achieved for 19 patients (73.1%), but the other seven pa-
tients exhibited positive resection margins (26.9%). A total of 
20 patients (76.9%) underwent ipsilateral parotidectomy: 12 
(46.2%) underwent superficial parotidectomy and eight (30.8%) 
underwent total parotidectomy. Twelve patients (46.2%) under-
went ipsilateral neck dissection: selective dissection in nine 
(34.6%), supraomohyoid dissection in two (7.7%), and modi-
fied radical neck dissection in one (3.8%). Additional surgical 
procedures were performed in three patients (11.5%). One pa-
tient with a T1 tumor underwent LTBR with resection of the 
temporomandibular joint (TMJ), facial nerve resection, and ca-
ble graft anastomosis. LTBR combined with TMJ resection was 
performed in one patient with a T2 tumor. In one patient with a 
T4 tumor, STBR using the infratemporal fossa approach, TMJ 
resection, facial nerve resection, cable graft anastomosis, and 
partial resection of the dura were performed. The histological 
diagnoses were well-differentiated SCC in 19 patients (73.1%), 
moderately differentiated SCC in six (23.1%), and poorly dif-
ferentiated SCC in one (3.8%). Grading reports for three cases 
were lacking. Postoperative adjuvant radiotherapy was prescribed 
for 12 patients (46%). One patient staged as T4N0M0 underwent 
neoadjuvant chemoradiotherapy before surgery (extended LTBR) 
and two patients with positive resection margins received adju-
vant chemotherapy. Treatment modalities according to the tumor 
stages are shown in Table 2.
Locoregional recurrence developed in six patients (23%) at a 
median follow-up time of 3.0 years (range, 1.1 to 7.9 years): 
three patients exhibited local failure, two had neck node recur-
rences, and one had both local and neck node recurrences (Table 
1). The recurrence rates were significantly higher in those of 
more advanced tumor stages: no pT1 patient experienced recur-
rence, but four, none, and two pT2, pT3, and pT4 cases, respec-
tively, experienced recurrences (P=0.014). Most recurrences (five 
Table 1. Baseline clinical characteristics of all patients with squa-
mous cell carcinomas of EAC and recurred cases  
Variable Total patients (n=26) Recurrence (n=6)  
Age (yr), median (range) 63 (17–84) 61 (42–76)
Sex (male:female) 16:10 4:2 
Location     
   Bony canal only 9 (33.3) 1 (16. 7)
   Cartilaginous canal only 4 (14.8) 2 (33.3)
   Bony & cartilaginous canal 8 (29.6) 2 (33.3)
   Not specified 5 (18.5) 1 (16.7)
Histology
   Well differentiated 16 (61.5) 1 (16.7)
   Moderately differentiated  6 (23.1) 1 (16.7)
   Poorly differentiated 1 (3.8) 3 (50.0)
   Not specified  3 (11.5) 1 (16.7)
T stage (modified Pittsburg)     
   T1 10 (37.0) 1 (16.7)
   T2  8 (29.6) 3 (50.0)
   T3  4 (14.8) 0
   T4 4 (14.8) 2 (33.3)
N stage (modified Pittsburg)     
   N1 24 (92.3) 6 (100)
   N2 1 (3.8) 0
   N3 1 (3.8) 0
   N4 0 0
Values are presented as number or number (%) unless otherwise indicated.
EAC, external auditory canal.
Table 2. Tumor stage-related treatment modalities (n=26) 
Variable
T1 
(n=10)
T2 
(n=8)
T3 
(n=4)
T4 
(n=4)
Type of surgery    
   Wide excision 2 0 1 0
   Lateral temporal bone resection 7 8 1 1
   Extended lateral temporal bone resection 1 0 2 1
   Subtotal temporal bone resection 0 0 0 2
Additional surgery
   Subtotal parotidectomy 6 1 4 1
   Total parotidectomy 1 4 0 3
   Neck dissection 4 3 2 3
Adjuvant treatment    
   Chemotherapy 0 1 1 1
   Radiotherapy 1 5 2 4
Fig. 1. Kaplan-Meier curves for overall survival (OS) and recurrence-
free survival (RFS) in patients with squamous cell carcinoma of the 
external auditory canal. The 5-year OS was 70.4% and RFS was 
61.8%.
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of six, 83.3%) were treated with adjuvant radiotherapy, and one 
patient with a pT2 tumor underwent chemotherapy. During fol-
low-up, four of the recurrent patients died of disease-related 
conditions.
Survival outcomes were analyzed for the 25 patients with fol-
low-up period of at least 1 year. The median follow-up period 
was 36.3 months (range, 2.2 to 98.6 months). The 5-year OS 
was 70.4% and RFS was 61.8% (Fig. 1). When various predic-
tive factors of the OS and RFS were analyzed using univariate 
analysis (Table 3), preoperative T stage (T2, T3, and T4 compared 
to T1) and preoperative overall stage (stages II, III, IV compared 
to stage I) were significantly associated with RFS, but not OS 
(P<0.05). Other variables such as age (>60 years vs. ≤60 
years), sex (male vs. female), presence of facial palsy or hearing 
loss, preoperative N stage (N1, N2, N3 vs. N0), types of surgery 
(ETBR and STBR vs. others), resection margins (positive vs. 
negative for malignancy), histologic grade (moderately or poorly 
differentiated vs. well-differentiated), pathologic T stage (T2, T3, 
T4 vs. T1), pathologic N stage (N1, N2, N3 vs. N0), final stage (II, 
III, IV vs. I), and addition of chemotherapy/radiotherapy did not 
show significant associated with survival outcomes.
DISCUSSION
 
In general, EAC cancer has a poor prognosis, and management 
remains challenging. Efforts have been made to identify prog-
nostic factors that can improve treatment protocols. Several dis-
ease-related factors such as tumor stage, a poorly differentiated 
cell type, neck lymph node involvement, and facial paralysis in-
dicate poor prognosis [8-11]. In terms of primary tumors, some 
studies have suggested that extensive local invasion, middle-ear 
involvement, facial nerve palsy, positive surgical margins, and 
cerebral involvement are associated with poor prognosis, where-
as others have reported that cerebral invasion is not a negative 
prognostic factor [6,11-14]. Ensuring that the margin is tumor-
free after surgical resection is important. Essig et al. [15] report-
ed a DFS rate of 81% at 2 years in patients with clear margins, 
in contrast to a DFS rate of 45% in patients with positive mar-
gins. Moody et al. [1] also reported that positive histological 
margins were associated with reduced survival at 2 years (32%) 
compared to that of patients with clear margins (75%) [1]. We 
found that the 2-year OS rate of patients with positive margins 
was poorer than that of those with clear margins (57.1% vs. 
81.3%). However, it should be noted that SCCs of the EAC are 
associated with a significant recurrence rate even in patients for 
whom postoperative pathological examinations reveal clear 
margins [16]. Nonetheless, the surgeon should consider wide en 
bloc resection to create oncologically safe margins, particularly 
of bone tissue, during the preoperative work-up [17].
A role for parotidectomy in treatment of advanced EAC can-
cer has been reported in many studies. We previously found that 
parotid invasion by SCC was only evident in advanced cases, 
and could be detected during preoperative evaluation [18]. In 
our study, although no patient exhibited lymph node involve-
ment on postoperative pathological examination, three patients 
developed nodal recurrences during follow-up. This affords a ra-
tionale for prophylactic parotidectomy and selective neck dis-
section when treating SCC in the EAC. Ihler et al. [5] reported 
that EAC cancer patients who did not undergo parotidectomy 
(with or without neck dissection) had a mean survival time 
shorter than the average of all EAC cancer patients. Although a 
consistent management strategy for the parotid gland has not 
emerged, recent studies have suggested that at least superficial 
Table 3. Univariate analysis of prognostic factors for OS and RFS in patients with squamous cell carcinoma of EAC (n=25) 
Variable
OS RFS
HR (95% CI) P-value HR (95% CI) P-value
Age 0.98 (0.92–1.05) 0.573 0.99 (0.94–1.06) 0.903
Sex 1.17 (0.26–5.24) 0.838 1.11 (0.30–4.17) 0.880
Facial nerve palsy, present   1.29 (0.06–27.87) 0.869   0.95 (0.05–19.42) 0.976
Hearing loss, present 1.03 (0.20–5.30) 0.974 0.67 (0.14-3.21) 0.612
Advanced preoperative T stage (T2, T3, T4)  13.74 (0.64–296.97) 0.095  8.57 (1.05–70.20) 0.045
Advanced preoperative N stage (N1, N2, N3) 1.45 (0.17–12.07) 0.733 1.15 (0.14–9.92) 0.896
Advanced preoperative stage (II, III, IV) 13.74 (0.64–296.97) 0.095 8.57 (1.05–70.20) 0.045
Types of surgery (ETBR, STBR) 2.23 (0.10–47.68) 0.608 3.00 (0.15–60.49) 0.474
Resection margin (positive for malignancy) 4.89 (0.94–25.48) 0.060 3.14 (0.81–12.19) 0.099
Histology grade (moderately-, poorly-differentiated) 0.15 (0.02–1.54) 0.110 0.28 (0.03–2.29) 0.253
Advanced pathologic T stage (T2, T3, T4) 10.28 (0.48–220.21) 0.136 15.16 (0.75–307.02) 0.077
Advanced pathologic N stage (N1, N2, N3) 6.11 (0.62–59.92) 0.120 2.61 (0.32–21.35) 0.371
Advanced final stage (II, III, IV) 10.28 (0.48–220.21) 0.136 15.16 (0.75–307.02) 0.077
Chemotherapy 0.22 (0.04–1.26) 0.089 0.41 (0.08–2.04) 0.275
Radiotherapy    2.27 (0.20–225.59) 0.508 2.58 (0.23–29.09) 0.444
OS, overall survival; RFS, recurrence-free survival; EAC, external auditory canal; HR, hazard ratio; CI, confidence interval; ETBR, extended temporal bone 
resection; STBR, subtotal temporal bone resection.     
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parotidectomy is required even when clinical evidence of lym-
phatic involvement is absent [4,6,8,17,19]. Mazzoni et al. [7] 
advocated total parotidectomy when the extent of anterior 
growth of the SCC extended beyond the anterior wall of the 
EAC, and prophylactic superficial parotidectomy for patients 
with T1 or T2 disease. The cited authors performed modified 
radical neck dissection to treat clinically positive lymph nodes, 
and selective prophylactic neck dissection in patients with clini-
cally negative necks who underwent LTBR, or STBR. Total pa-
rotidectomy was recommended for patients with advanced 
SCCs [20].
Although SCC is the most common histological type of tem-
poral bone neoplasm, other carcinoma subtypes include basal 
cell carcinoma, adenocarcinoma, adenoid cystic carcinoma, mu-
coepidermoid carcinoma, melanoma, and sarcoma. In addition, 
some studies included parotid gland tumors invading the EAC 
and SCCs arising from the auricle as EAC cancers. As histologi-
cal subtype may be a confounding factor, we only collected data 
from histologically confirmed SCCs. SCCs of the EAC are asso-
ciated with poorer prognoses than other pathologies. Treatment 
outcomes have improved over the past several decades because 
of advances in imaging modalities and microsurgical and chemo-
radiotherapeutic techniques. In a review of the literature, Prasad 
et al. [21] reported the 2-year survival rates of patients with 
temporal bone cancers by grade: T1 (48%–100%), T2 (28%–
100%), T3 (17%–100%), and T4 (14.3%–54.0%). The authors 
attributed the wide ranges to difficulties in collecting data on a 
rare disease and the use of different treatment modalities [21]. 
In our study, the OS rate was 75.4% and the 5-year survival 
rates were as follows: T1 (90.0%), T2 (44.0%), T3 (75.0%), and 
T4 (40.0%). In another study seeking predictors of survival/re-
currence after temporal bone resection, the relevant predictors 
were the status of the surgical margin, metastatic lymph nodes 
in the neck or parotid, and parotid invasion [22]. Our results in-
dicated that only T stage, which is associated with the difficulty 
achieving a safe margin because of the complex anatomy and 
surrounding vital tissues, affected OS and DFS. The survival 
rates of patients with SCCs of the EAC who undergo surgery at 
early stages are reportedly favorable, highlighting the impor-
tance of clinical suspicion and early diagnosis. The results of our 
study have been summarized along with the results of contem-
porary series in Table 4 [1,3,4,6-10,12,14,15,23-28].
The greatest limitations of our study were the small number 
of patients, particularly those of tumor stages T3 and T4, and the 
limited follow-up period. Detailed longer-term follow-up of larg-
er cohorts of patients with all stages of disease would be invalu-
able to strengthen the statistical analysis. In addition, more com-
prehensive information on prognostic factors would provide 
much-needed evidence that would allow the treatment guide-
lines for SCC of the EAC to be refined. 
In conclusion, we identified that preoperatively advanced tu-
mor stages are related to decreased survival outcomes in pa-
tients with SCC of the EAC who underwent surgical treatment. 
Our results highlight the importance of clinical vigilance and 
early detection of EAC lesions. However, further studies with 
comprehensive evaluation for clinical and surgical prognostic 
factors would provide better insight to surgical outcomes for 
SCC of the EAC.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
ACKNOWLEDGMENTS
We would like to thank Dr. Hye Sun Lee and Ms. Sinae Kim of 
the Biostatistics Collaboration Unit, Yonsei University College of 
Medicine for their contributions to this work and their construc-
tive collaboration.
This research was supported by the Basic Science Research 
Program of the National Research Foundation of Korea (NRF), 
funded by the Ministry of Education, Science and Technology 
(Grant No. 2016R1A2B1012521 to EJS), Republic of Korea, 
and by a faculty research grant from Yonsei University College 
of Medicine (6-2016-0040), Seoul, Korea.
 
REFERENCES
1. Moody SA, Hirsch BE, Myers EN. Squamous cell carcinoma of the 
external auditory canal: an evaluation of a staging system. Am J 
Otol. 2000 Jul;21(4):582-8.
2. Zhang T, Dai C, Wang Z. The misdiagnosis of external auditory canal 
carcinoma. Eur Arch Otorhinolaryngol. 2013 May;270(5):1607-13.
3. Arriaga M, Curtin H, Takahashi H, Hirsch BE, Kamerer DB. Staging 
proposal for external auditory meatus carcinoma based on preoper-
ative clinical examination and computed tomography findings. Ann 
Otol Rhinol Laryngol. 1990 Sep;99(9 Pt 1):714-21.
4. Lassig AA, Spector ME, Soliman S, El-Kashlan HK. Squamous cell 
carcinoma involving the temporal bone: lateral temporal bone re-
section as primary intervention. Otol Neurotol. 2013 Jan;34(1):141-
50.
5. Ihler F, Koopmann M, Weiss BG, Droge LH, Durisin M, Christiansen 
H, et al. Surgical margins and oncologic results after carcinoma of 
the external auditory canal. Laryngoscope. 2015 Sep;125(9):2107-
12.
6. Moffat DA, Wagstaff SA, Hardy DG. The outcome of radical surgery 
and postoperative radiotherapy for squamous carcinoma of the tem-
poral bone. Laryngoscope. 2005 Feb;115(2):341-7.
7. Mazzoni A, Danesi G, Zanoletti E. Primary squamous cell carcinoma 
of the external auditory canal: surgical treatment and long-term 
outcomes. Acta Otorhinolaryngol Ital. 2014 Apr;34(2):129-37.
8. Leong SC, Youssef A, Lesser TH. Squamous cell carcinoma of the 
temporal bone: outcomes of radical surgery and postoperative ra-
diotherapy. Laryngoscope. 2013 Oct;123(10):2442-8.
9. Lobo D, Llorente JL, Suarez C. Squamous cell carcinoma of the ex-
266    Clinical and Experimental Otorhinolaryngology    Vol. 11, No. 4: 259-266, December 2018
ternal auditory canal. Skull Base. 2008 May;18(3):167-72.
10. Gandhi AK, Roy S, Biswas A, Raza MW, Saxena T, Bhasker S, et al. 
Treatment of squamous cell carcinoma of external auditory canal: a 
tertiary cancer centre experience. Auris Nasus Larynx. 2016 Feb; 
43(1):45-9.
11. Ouaz K, Robier A, Lescanne E, Bobillier C, Moriniere S, Bakhos D. 
Cancer of the external auditory canal. Eur Ann Otorhinolaryngol 
Head Neck Dis. 2013 Sep;130(4):175-82.
12. Yin M, Ishikawa K, Honda K, Arakawa T, Harabuchi Y, Nagabashi T, 
et al. Analysis of 95 cases of squamous cell carcinoma of the exter-
nal and middle ear.  Auris Nasus Larynx. 2006 Sep;33(3):251-7.
13. Hosokawa S, Mizuta K, Takahashi G, Okamura J, Takizawa Y, Hoso-
kawa K, et al. Carcinoma of the external auditory canal: histological 
and treatment groups. B-ENT. 2014;10(4):259-64.
14. Kunst H, Lavieille JP, Marres H. Squamous cell carcinoma of the 
temporal bone: results and management. Otol Neurotol. 2008 Jun; 
29(4):549-52.
15. Essig GF, Kitipornchai L, Adams F, Zarate D, Gandhi M, Porceddu S, 
et al. Lateral temporal bone resection in advanced cutaneous squa-
mous cell carcinoma: report of 35 patients. J Neurol Surg B Skull 
Base. 2013 Feb;74(1):54-9.
16. Marioni G, Martini A, Favaretto N, Franchella S, Cappellesso R, Ma-
rino F, et al. Temporal bone carcinoma: a first glance beyond the 
conventional clinical and pathological prognostic factors. Eur Arch 
Otorhinolaryngol. 2016 Oct;273(10):2903-10.
17. Zanoletti E, Marioni G, Franchella S, Lovato A, Giacomelli L, Marti-
ni A, et al. Recurrent squamous cell carcinoma of the temporal 
bone: critical analysis of cases with a poor prognosis. Am J Otolar-
yngol. 2015 May-Jun;36(3):352-5.
18. Choi JY, Choi EC, Lee HK, Yoo JB, Kim SG, Lee WS. Mode of parot-
id involvement in external auditory canal carcinoma. J Laryngol 
Otol. 2003 Dec;117(12):951-4.
19. Xie B, Zhang T, Dai C. Survival outcomes of patients with temporal 
bone squamous cell carcinoma with different invasion patterns. 
Head Neck. 2015 Feb;37(2):188-96.
20. Homer JJ, Lesser T, Moffat D, Slevin N, Price R, Blackburn T. Man-
agement of lateral skull base cancer: United Kingdom National 
Multidisciplinary Guidelines. J Laryngol Otol. 2016 May;130(S2): 
S119-24.
21. Prasad SC, D’Orazio F, Medina M, Bacciu A, Sanna M. State of the 
art in temporal bone malignancies. Curr Opin Otolaryngol Head 
Neck Surg. 2014 Apr;22(2):154-65.
22. Morris LG, Mehra S, Shah JP, Bilsky MH, Selesnick SH, Kraus DH. 
Predictors of survival and recurrence after temporal bone resection 
for cancer. Head Neck. 2012 Sep;34(9):1231-9.
23. Arriaga M, Hirsch BE, Kamerer DB, Myers EN. Squamous cell carci-
noma of the external auditory meatus (canal). Otolaryngol Head 
Neck Surg. 1989 Sep;101(3):330-7.
24. Austin JR, Stewart KL, Fawzi N. Squamous cell carcinoma of the exter-
nal auditory canal: therapeutic prognosis based on a proposed staging 
system. Arch Otolaryngol Head Neck Surg. 1994 Nov;120(11):1228-
32.
25. Hashi N, Shirato H, Omatsu T, Kagei K, Nishioka T, Hashimoto S, et 
al. The role of radiotherapy in treating squamous cell carcinoma of 
the external auditory canal, especially in early stages of disease. Ra-
diother Oncol. 2000 Aug;56(2):221-5.
26. Stell PM, McCormick MS. Carcinoma of the external auditory me-
atus and middle ear: prognostic factors and a suggested staging sys-
tem. J Laryngol Otol. 1985 Sep;99(9):847-50.
27. Gillespie MB, Francis HW, Chee N, Eisele DW. Squamous cell carci-
noma of the temporal bone: a radiographic-pathologic correlation. 
Arch Otolaryngol Head Neck Surg. 2001 Jul;127(7):803-7.
28. Bacciu A, Clemente IA, Piccirillo E, Ferrari S, Sanna M. Guidelines 
for treating temporal bone carcinoma based on long-term outcomes. 
Otol Neurotol. 2013 Jul;34(5):898-907.
